Top holdings include Illumina 10.1%, Invitae Corp 8.3%, Intellia Therapeutics 7.4%, Editas Medicine 6.5% and Medidata Slutions 5.2%. CRISPR Therapeutics is 4.2% of the fund’s holdings.
The fund tries to help investors take on a thematic multi-capitalization exposure to innovative elements that cover advancements in gene therapy bio-informatics, bio-inspired computing, molecular medicine, and pharmaceutical innovations. These advancements can also translate over to growth potential, potentially providing investors with long-term alpha with low correlation relative to traditional growth strategies.
Furthermore, the active management team behind the ARKG strategy combines a top-down and bottom-up research methodology to identify innovative companies and convergence across markets.
Financial advisors who are interested in learning more about a biotechnology growth opportunity can register for the Tuesday, December 4 webcast here.